Cargando…

Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation

PURPOSE: To develop an evidence-based clinical practice guideline for the prevention of oral mucositis in children (0–18 years) receiving treatment for cancer or undergoing haematopoietic stem cell transplantation (HSCT). METHODS: The Mucositis Prevention Guideline Development Group was interdiscipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Lillian, Robinson, Paula, Treister, Nathaniel, Baggott, Tina, Gibson, Paul, Tissing, Wim, Wiernikowski, John, Brinklow, Jennifer, Dupuis, L Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339548/
https://www.ncbi.nlm.nih.gov/pubmed/25818385
http://dx.doi.org/10.1136/bmjspcare-2014-000804
_version_ 1782512681282961408
author Sung, Lillian
Robinson, Paula
Treister, Nathaniel
Baggott, Tina
Gibson, Paul
Tissing, Wim
Wiernikowski, John
Brinklow, Jennifer
Dupuis, L Lee
author_facet Sung, Lillian
Robinson, Paula
Treister, Nathaniel
Baggott, Tina
Gibson, Paul
Tissing, Wim
Wiernikowski, John
Brinklow, Jennifer
Dupuis, L Lee
author_sort Sung, Lillian
collection PubMed
description PURPOSE: To develop an evidence-based clinical practice guideline for the prevention of oral mucositis in children (0–18 years) receiving treatment for cancer or undergoing haematopoietic stem cell transplantation (HSCT). METHODS: The Mucositis Prevention Guideline Development Group was interdisciplinary and included internationally recognised experts in paediatric mucositis. For the evidence review, we included randomised controlled trials (RCTs) conducted in either children or adults evaluating the following interventions selected according to prespecified criteria: cryotherapy, low level light therapy (LLLT) and keratinocyte growth factor (KGF). We also examined RCTs of any intervention conducted in children. For all systematic reviews, we synthesised the occurrence of severe oral mucositis. The Grades of Recommendation, Assessment, Development and Evaluation approach was used to describe quality of evidence and strength of recommendations. RESULTS: We suggest cryotherapy or LLLT may be offered to cooperative children receiving chemotherapy or HSCT conditioning with regimens associated with a high rate of mucositis. We also suggest KGF may be offered to children receiving HSCT conditioning with regimens associated with a high rate of severe mucositis. However, KGF use merits caution as there is a lack of efficacy and toxicity data in children, and a lack of long-term follow-up data in paediatric cancers. No other interventions were recommended for oral mucositis prevention in children. CONCLUSIONS: All three specific interventions evaluated in this clinical practice guideline were associated with a weak recommendation for use. There may be important organisational and cost barriers to the adoption of LLLT and KGF. Considerations for implementation and key research gaps are highlighted.
format Online
Article
Text
id pubmed-5339548
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53395482017-03-20 Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation Sung, Lillian Robinson, Paula Treister, Nathaniel Baggott, Tina Gibson, Paul Tissing, Wim Wiernikowski, John Brinklow, Jennifer Dupuis, L Lee BMJ Support Palliat Care Review PURPOSE: To develop an evidence-based clinical practice guideline for the prevention of oral mucositis in children (0–18 years) receiving treatment for cancer or undergoing haematopoietic stem cell transplantation (HSCT). METHODS: The Mucositis Prevention Guideline Development Group was interdisciplinary and included internationally recognised experts in paediatric mucositis. For the evidence review, we included randomised controlled trials (RCTs) conducted in either children or adults evaluating the following interventions selected according to prespecified criteria: cryotherapy, low level light therapy (LLLT) and keratinocyte growth factor (KGF). We also examined RCTs of any intervention conducted in children. For all systematic reviews, we synthesised the occurrence of severe oral mucositis. The Grades of Recommendation, Assessment, Development and Evaluation approach was used to describe quality of evidence and strength of recommendations. RESULTS: We suggest cryotherapy or LLLT may be offered to cooperative children receiving chemotherapy or HSCT conditioning with regimens associated with a high rate of mucositis. We also suggest KGF may be offered to children receiving HSCT conditioning with regimens associated with a high rate of severe mucositis. However, KGF use merits caution as there is a lack of efficacy and toxicity data in children, and a lack of long-term follow-up data in paediatric cancers. No other interventions were recommended for oral mucositis prevention in children. CONCLUSIONS: All three specific interventions evaluated in this clinical practice guideline were associated with a weak recommendation for use. There may be important organisational and cost barriers to the adoption of LLLT and KGF. Considerations for implementation and key research gaps are highlighted. BMJ Publishing Group 2017-03 2015-03-27 /pmc/articles/PMC5339548/ /pubmed/25818385 http://dx.doi.org/10.1136/bmjspcare-2014-000804 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
Sung, Lillian
Robinson, Paula
Treister, Nathaniel
Baggott, Tina
Gibson, Paul
Tissing, Wim
Wiernikowski, John
Brinklow, Jennifer
Dupuis, L Lee
Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
title Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
title_full Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
title_fullStr Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
title_full_unstemmed Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
title_short Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
title_sort guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339548/
https://www.ncbi.nlm.nih.gov/pubmed/25818385
http://dx.doi.org/10.1136/bmjspcare-2014-000804
work_keys_str_mv AT sunglillian guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation
AT robinsonpaula guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation
AT treisternathaniel guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation
AT baggotttina guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation
AT gibsonpaul guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation
AT tissingwim guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation
AT wiernikowskijohn guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation
AT brinklowjennifer guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation
AT dupuisllee guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation